Second-Line Therapy in Advanced HCC: Treatment Considerations and Evolving Options
Panelists discuss how, when a patient progresses to second-line therapy, key considerations include prior treatment response, toxicity, patient comorbidities, and therapeutic goals. Lenvatinib shows potential beyond first-line treatment, offering efficacy in patients progressing on systemic therapies, with emerging data supporting its role in treatment sequencing.
Video content above is prompted by the following:
- What treatment considerations arise when a patient progresses and requires second-line therapy?
- Discuss the potential for lenvatinib beyond first-line treatment in patients progressing on systemic therapies.
Recent Videos
